8-K: Xtant Medical Holdings Updates Financials Following Surgalign Acquisition

Xtant Medical Holdings files updated financial statements for Surgalign Holdings and pro forma information following the acquisition of Surgalign's assets.

Summary

• Xtant Medical Holdings has filed an 8-K report including updated financial statements for Surgalign Holdings for the six months ended June 30, 2023, and the year ended December 31, 2022.
• The report also includes pro forma financial information for the year ended December 31, 2023, reflecting the acquisition of Surgalign's assets.
• The acquisition was completed on August 10, 2023, and the updated financials supplement previous filings.
• The pro forma information is for informational purposes only and does not represent actual or future operating results.
• Surgalign's unaudited revenues for the six months ended June 30, 2023, were $30.3 million, down from $41.2 million in the same period of 2022.
• Surgalign reported a net income of $5.8 million for the six months ended June 30, 2023, compared to a net loss of $5.7 million for the same period in 2022.
• The pro forma combined revenue for Xtant and Surgalign for the year ended December 31, 2023, is $126.2 million.
• The pro forma net loss for the combined entity is $0.2 million for the year ended December 31, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with improved net income for Surgalign but decreased revenue and a pro forma net loss for the combined entity. The acquisition is a positive step, but the financial results suggest ongoing challenges.

Positives

• Surgalign's net income improved significantly, from a loss of $5.7 million to a profit of $5.8 million for the six months ended June 30, 2023, compared to the same period in 2022.
• The acquisition of Surgalign's assets by Xtant is expected to increase the combined company's revenue to $126.2 million for the year ended December 31, 2023.

Negatives

• Surgalign's revenue decreased from $41.2 million to $30.3 million for the six months ended June 30, 2023, compared to the same period in 2022.
• The pro forma net loss for the combined entity is $0.2 million for the year ended December 31, 2023.

Risks

• The pro forma financial information is for informational purposes only and may not reflect actual future results.
• The acquisition was conducted through a bankruptcy process, limiting representations and warranties.
• The actual results and valuations may differ materially from the assumptions within the pro forma financial statements.
• The company has a history of net losses and negative cash flows.

Future Outlook

The pro forma financial information is for informational purposes only and does not represent actual or future operating results of the combined company.

Industry Context

The acquisition of Surgalign's assets by Xtant is part of a broader trend of consolidation in the medical device industry, where companies seek to expand their product portfolios and market reach through strategic acquisitions.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without more specific information on the product mix and market segments of Surgalign and Xtant.
• However, the decrease in Surgalign's revenue and the pro forma net loss for the combined entity suggest that the company is facing challenges in a competitive market.
• Companies like Medtronic, Johnson & Johnson, and Stryker are major players in the medical device industry and have significantly larger revenues and market capitalization than Xtant and Surgalign.
• The pro forma results indicate that the combined entity is still in a growth phase and needs to improve its profitability to compete effectively with industry leaders.

Legal Proceedings

• The company is involved in ongoing litigation, including a patent infringement lawsuit with LifeNet Health, and is defending itself vigorously.
• The company was previously involved in a securities class action and derivative lawsuits, which have been settled.

Related Party Transactions

• The company is not aware of any related party transactions in 2023 to date.

Stakeholder Impact

• Shareholders will be impacted by the acquisition and the updated financial results.
• Employees may be affected by the integration of the two companies.
• Customers may see changes in product offerings and services.
• Suppliers may be impacted by changes in purchasing and supply chain management.

Next Steps

• Xtant intends to file a registration statement on Form S-3 with the SEC.
• The company will need to integrate the acquired assets and operations of Surgalign.

Key Dates

Keywords

acquisition, financial statements, pro forma, Surgalign, Xtant Medical, assets, revenue, net income, medical devices, bankruptcy